Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glesatinib in MET-altered NSCLC
NCT02544633Phase 2Completed
- Sponsor
- Mirati Therapeutics
- Start
- Oct 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of glesatinib in non-small cell lung cancer (NSCLC), sponsored by Mirati Therapeutics. Started Oct 2015; status: completed.
02
Drugs
glesatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02544633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02544633.